Promega Sustainability Profile
Promega Corporation, a leading biotechnology company headquartered in the United States, has been at the forefront of life sciences since its founding in 1978. With a strong presence in North America, Europe, and Asia, Promega focuses on providing innovative solutions for molecular biology, genomics, and protein analysis. The company is renowned for its core products, including luciferase-based assays, DNA and RNA purification kits, and cell culture reagents, which are distinguished by their reliability and ease of use. Promega's commitment to quality and innovation has solidified its position as a trusted partner in research and development across various industries, including pharmaceuticals, diagnostics, and academic research. Notable achievements include numerous patents and a robust portfolio that supports advancements in scientific discovery, making Promega a pivotal player in the global biotechnology landscape.
DitchCarbon Score
How does Promega's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Promega's score of 49 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Promega's reported carbon emissions
In 2024, Promega Corporation reported total carbon emissions of approximately 31,616,000 kg CO2e, a decrease from about 37,073,000 kg CO2e in 2023. The emissions breakdown for 2024 includes 10,765,000 kg CO2e from Scope 1, 6,214,000 kg CO2e from Scope 2, and 14,637,000 kg CO2e from Scope 3. This trend indicates a commitment to reducing their carbon footprint, particularly in Scope 1 and Scope 2 emissions. Promega has set near-term targets as part of their climate commitments, with a status of "Committed" to the Science Based Targets initiative (SBTi). However, specific reduction targets have not been disclosed. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in the United States. Over the past few years, Promega has shown a consistent effort to lower emissions, with total emissions decreasing from about 48,052,000 kg CO2e in 2022 and 50,428,000 kg CO2e in 2021. This reflects a proactive approach to sustainability and climate responsibility, aligning with industry standards for emissions reporting and reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 8,158,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21,281,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 12,571,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Promega's Industry?
How Carbon Intensive is Promega's Location?
Promega's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Promega has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Promega's sustainability data and climate commitments